Antimicrobial resistance, the ability of bacteria and other microorganisms to survive drugs designed to kill them, has been described by scientists for years as a slow moving pandemic. In late November 2025, one of India's most significant policy and science events on this subject took place at Amrita Hospital, Faridabad. The two day national conclave, AMR NEXT 2025, brought together government officials, international health experts, researchers, and clinicians under one theme: "Transformative Strategies to Tackle Antimicrobial Resistance: For a Safer Tomorrow."
This article looks back at what happened at the conclave, what the experts said, and more importantly, what it means for patients, healthcare seekers, and the global health community.
What Was AMR NEXT 2025?
AMR NEXT 2025 was a national conclave held on November 29-30, 2025, at Amrita Hospital in Faridabad, Haryana. Organized under the leadership of Amrita Hospital, the event drew top voices from government health policy, academia, public health, biotechnology, and international institutions.
The goal was straightforward: to move beyond awareness and into action. At a time when drug resistant infections are claiming more lives worldwide, the conclave offered a structured platform to share surveillance data, discuss stewardship gaps, showcase diagnostic and therapeutic innovations, and align policies across sectors.
Discussions spanned diagnostics, antimicrobial stewardship, new drug development pipelines, environmental and agricultural dimensions of AMR, and the critical need for coordinated cross border cooperation, all in the context of India's unique disease burden and healthcare landscape.
Why India Needs Conversations Like This
India carries one of the world's highest burdens of bacterial infections. This is not a new problem, but the data coming out of national surveillance programs make it increasingly urgent.
Bacteria such as E. coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii, organisms responsible for a wide range of common hospital and community infections, continue to show high resistance rates across the country. Data from the Indian Council of Medical Research (ICMR) does indicate modest improvements in some areas: susceptibility of E. coli to ceftazidime, for example, appeared to improve between 2023 and 2024. However, experts at the conclave were clear eyed about the bigger picture. Resistance to last resort drugs, carbapenems and colistin, continues to be a serious concern, and that means doctors are running out of reliable treatment options for some infections.
The drivers of resistance in India are well recognized. They include the country's high infectious disease burden, irrational and excessive antibiotic use in both human healthcare and animal husbandry, unregulated over the counter sale of antibiotics, insufficient diagnostic stewardship, pharmaceutical manufacturing waste entering water systems, and hospital effluents contaminating the broader environment. Together, these factors interact in ways that accelerate resistance across the population.
The economic consequences are also tangible. Longer hospitalizations, higher treatment costs, and reduced worker productivity all feed into a growing economic burden, one that disproportionately affects lower-income patients and already stretched public health systems.
What the Experts Said
Dr. Sanjeev Singh, Medical Director of Amrita Hospital, Faridabad, framed the challenge directly: antimicrobial resistance is increasing mortality, extending hospital stays, and driving up the cost of care. His message was that no single institution, and no single country, can solve this alone. Coordinated, cross sector, cross border action is not optional, it is the only viable strategy.
Smt. Anupriya Patel, Union Minister of State for Health and Family Welfare, presented India's progress under the National Action Plan on AMR. She highlighted expanded laboratory capacity, standardized testing protocols, and the integration of human, animal, and environmental surveillance data, all in alignment with One Health principles. This integrated approach, she noted, allows India to detect emerging resistance trends more rapidly and contribute more meaningful data to global surveillance systems coordinated by the World Health Organization.
Professor Alison Holmes OBE, Lead for the Centres for Antimicrobial Optimization Network and Director of the Fleming Initiative at Imperial College London, offered an international perspective. Her message echoed what public health scientists have been saying for years: AMR does not recognize national borders or economic categories. The response must be equally borderless. She called for stronger international research collaboration to accelerate solutions, not just better diagnostics and new drugs, but the fundamental cultural and systemic changes in how antibiotics are prescribed and used.
What AMR Actually Means for Patients
For the average patient or healthcare traveler, the term "antimicrobial resistance" can feel abstract. In practice, its implications are concrete.
When bacteria become resistant to standard antibiotics, a routine infection, a urinary tract infection, a post-surgical wound infection, a case of pneumonia, can become difficult or impossible to treat. A drug that would have cleared an infection in a week may no longer work. Doctors are then forced to use second or third line antibiotics that are more expensive, may have more side effects, and are increasingly showing resistance themselves.
For international patients seeking treatment in India, whether for cardiac surgery, oncology, orthopedics, or any major procedure, hospital acquired infections are a real consideration. Choosing hospitals with strong infection prevention and control programs, antimicrobial stewardship protocols, and transparent resistance data is increasingly part of making an informed healthcare decision.
Innovation Showcase: The Emerging Toolbox
One of the highlights of AMR NEXT 2025 was a dedicated innovation showcase, where emerging technologies were on display. Areas of focus included:
- Rapid diagnostics: Technologies that allow faster and more precise identification of the causative organism and its resistance profile, reducing the window during which broad spectrum antibiotics are used empirically.
- Digital health tools: Software and AI-based platforms supporting antimicrobial stewardship by helping clinicians make better prescribing decisions in real time.
- Antimicrobial optimization: Tools and protocols aimed at ensuring the right drug, at the right dose, for the right duration reducing both treatment failure and resistance development.
- Infection prevention technologies: Advanced approaches to hospital hygiene, surface decontamination, and barrier precautions that reduce the spread of resistant organisms within healthcare settings.
These innovations do not make the problem go away overnight, but they represent genuine progress the kind that, scaled up with policy backing, can begin to bend the curve on resistance rates.
The One Health Connection
A key theme at the conclave was the One Health framework, the recognition that human health, animal health, and environmental health are deeply interconnected. AMR does not begin and end in hospitals. Antibiotic use in livestock, poultry, and aquaculture contributes to the pool of resistant organisms that can eventually reach humans. Pharmaceutical waste from manufacturing facilities and hospitals enters soil and water systems, creating environmental reservoirs of resistance genes.
India's National Action Plan on AMR explicitly incorporates One Health surveillance, tracking resistance across human, animal, and environmental sectors together. The conclave reinforced why this is not just scientific elegance but practical necessity. Addressing AMR requires agriculture ministries working alongside health ministries, environmental regulators collaborating with pharmaceutical manufacturers, and global coordination connecting it all.
What This Means Going Forward
AMR NEXT 2025 was not a one time alarm bell. It represented a maturing conversation in India, one that has moved from describing the problem to building systems for solution. The data gaps are narrowing, the policy frameworks are strengthening, and the innovation ecosystem is beginning to deliver tools that can be used in real world clinical practice.
For patients, the practical implications are about awareness and advocacy. Understanding that antibiotic resistance is shaped by everyday prescribing choices, including whether you take a full antibiotic course, whether antibiotics are requested for viral infections, and whether medications are purchased without a prescription, means that individual behavior genuinely contributes to the collective outcome.
For those seeking medical treatment in India or abroad, it is worth asking healthcare providers about their stewardship programs, their infection rates, and their resistance monitoring protocols. These are not just quality metrics, they are patient safety markers.
Conclusion
The AMR NEXT 2025 conclave at Amrita Hospital, Faridabad was a significant moment in India's ongoing effort to confront antimicrobial resistance with the seriousness it demands. With contributions from government, international academia, clinical leadership, and technology innovators, the event reinforced that the path forward requires collaboration at every level, within hospitals, across health sectors, and across national borders.
Drug resistance is not an abstract threat on a distant horizon. It is a present reality, playing out in wards and clinics every day. Events like AMR NEXT 2025 exist to make sure that reality is met with science, policy, and coordinated action, and to keep the issue firmly in public and professional consciousness until the trajectory begins to change.
References
- Amrita Vishwa Vidyapeetham. (November 30, 2025). Drug Resistance Threat Deepens, AMR NEXT 2025 at Amrita Hospital, Faridabad Witnesses National and Global Expertise. https://www.amrita.edu/news/drug-resistance-threat-deepens-amr-next-2025-at-amrita-hospital-faridabad-witness-national-and-global-expertise/
- Indian Council of Medical Research (ICMR). Annual AMR Surveillance Network Reports.
- World Health Organization. Antimicrobial Resistance: Global Action Plan. https://www.who.int/publications/i/item/9789241509763
About Hospidio: This blog post is intended to provide factual, evidence based information to keep our community informed about global health developments. Always consult with healthcare professionals for medical advice and follow guidance from your local health authorities.
Recent Blogs
Shruti Verma has completed her M.Tech in Biotechnology with experience in medical writing and scientific content development. She specializes in translating complex biomedical and healthcare information into clear, accurate, and reader-friendly content for diverse audiences. When she is not designing content, probably she is designing graphics.
Guneet Bhatia is the Founder of HOSPIDIO and an accomplished content reviewer with extensive experience in medical content development, instructional design, and blogging. Passionate about creating impactful content, she excels in ensuring accuracy and clarity in every piece. Guneet enjoys engaging in meaningful conversations with people from diverse ethnic and cultural backgrounds, enriching her perspective. When she's not working, she cherishes quality time with her family, enjoys good music, and loves brainstorming innovative ideas with her team.